Companion Animal Cancer Vaccine Development

Inquiry Now

Cancer vaccines tailored for companion animals including dogs and cats serve two main purposes. Preventive vaccines function by instructing the animal's immune system to mount a response against tumor antigens, thereby thwarting cancer cell growth. Therapeutic vaccines contribute to treating and easing the impact of existing cancer in animals. Moreover, these vaccines play a pivotal role in minimizing the chances of cancer relapse by activating the immune system. BioVenic offers comprehensive development services for both animal preventive and therapeutic cancer vaccines, boasting established platforms that accommodate various veterinary vaccine strategies.

Our Services

Animal Cancer Preventive Vaccine Development

The veterinary preventive cancer vaccine guides the immune system to generate an immune response against specific cancer antigens, thereby impeding the growth and spread of cancer cells. BioVenic has established multiple platforms for veterinary preventive cancer vaccine development, offering a comprehensive approach to safeguarding the health of companion animals.

Platforms	Description
Virus Veterinary Vaccine	For animal cancers induced by viruses, the approach involves introducing inactivated viruses or subunit antigens, as well as nucleic acid antigens, to stimulate the animal's immune system to generate a defensive immune response against these antigens.
Neo-Antigen Vaccine	Genomic analysis of tumor tissues is conducted to identify specific mutated antigens, known as neo-antigens. These neo-antigens are utilized in vaccine preparation, activating the immune system of non-cancerous animals, thereby providing a more personalized and precise immunoprotection against cancer.

Animal Cancer Therapeutic Vaccine Development

Animal therapeutic cancer vaccines are primarily applied to individuals who have already developed cancer. These vaccines aim to enhance the sensitivity of the immune system, harnessing its power to evoke specific immune responses against cancer cells. By promoting the inherent anti-cancer capabilities of the immune system, these vaccines offer a comprehensive and systematic approach to treating animals.

Fig.1 Several types of cancer vaccines for therapeutic use in companion animals.¹

BioVenic has established various technical platforms for therapeutic cancer vaccine development in companion animals. These platforms include highly personalized autogenous vaccines, as well as peptide-based, nucleic acid-based vaccines and recombinant vectored veterinary vaccines targeting tumor antigens.

Platforms	Description
Autogenous Veterinary Cancer Vaccine	Extracting tumor tissue from animals with cancer, processing, and preparing the vaccine to stimulate the immune system's response against tumors. This vaccine is tailored to the individual's cancer characteristics, displaying a highly personalized nature.
Dendritic Cell Veterinary Vaccine	Extracting dendritic cells from animals with cancer, processing them in the laboratory, and reintroducing them into the animal. Leveraging the antigen-presenting function of dendritic cells, tumor-associated antigens are introduced into the immune system, stimulating an immune response against cancer.
Peptide-Based Veterinary Vaccine	Stimulating the immune system to generate a response against cancer antigens by using specific peptide segments associated with tumor antigens. Compared to the entire protein, peptide-based vaccines have more precise targeting and greater specificity.
Nuclear Acid-Based Veterinary Vaccine	Using DNA or RNA molecules encoding antigens associated with cancer. By transcribing and translating these molecules within host cells, cancer antigens are produced, eliciting an immune response.
Recombinant Vectored Veterinary Vaccine	Using viral or bacterial vectors, specific genes associated with tumor antigens are delivered to diseased animals, triggering an immune response that targets and attacks the cancer cells.

Why Choose Us?

We offer comprehensive companion animal cancer vaccine development services, covering both preventive and therapeutic aspects.
Our diverse cancer vaccine development technological platforms are tailored to meet your specific research needs.
One-stop vaccine development solution from animal cancer target discovery to preclinical CRO services and in vitro and in vivo safety and efficacy assessments.

BioVenic's services span from target discovery and antigen preparation to later-stage safety and efficacy assessments, ensuring that companion animals receive efficient, safe, and personalized cancer immunoprotection. Please contact us for professional support of companion animal preventive and therapeutic cancer vaccine development, let us assist you in achieving success!

Reference

Anderson, Katie L., and Jaime F. Modiano. "Progress in adaptive immunotherapy for cancer in companion animals: success on the path to a cure." Veterinary sciences 2.4 (2015): 363-387.